Author
Y N Belenkov
Bio: Y N Belenkov is an academic researcher from I.M. Sechenov First Moscow State Medical University. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 9, co-authored 26 publications receiving 505 citations.
Papers
More filters
Imperial College London1, Duke University2, The Royal Marsden NHS Foundation Trust3, University of Cambridge4, Mount Sinai Hospital, Toronto5, University of Paris6, Vanderbilt University Medical Center7, Brigham and Women's Hospital8, Medical University of Vienna9, University of Melbourne10, National University of Singapore11, Charité12, University of Göttingen13, Charles University in Prague14, Georgetown University15, University Health Network16, University of Pennsylvania17, Harvard University18, Tel Aviv University19, University of Newcastle20, University of São Paulo21, University College London22, University of Cyprus23, National and Kapodistrian University of Athens24, University Medical Center Groningen25, American University of Beirut26, University of Bern27, European Institute of Oncology28, Stanford University29, Mayo Clinic30, Memorial Sloan Kettering Cancer Center31, University of Zurich32, University of Warwick33, Serbian Academy of Sciences and Arts34, Hannover Medical School35, Hospital Universitario La Paz36, Newcastle upon Tyne Hospitals NHS Foundation Trust37, Washington University in St. Louis38
TL;DR: In this paper, the authors presented a risk stratification proformas for oncology patients prior to receiving cancer therapies known to cause heart failure or other serious cardiovascular toxicities, with the aim of improving personalised approaches to minimise the risk of cardiovascular toxicity from cancer therapies.
Abstract: This position statement from the Heart Failure Association of the European Society of Cardiology Cardio-Oncology Study Group in collaboration with the International Cardio-Oncology Society presents practical, easy-to-use and evidence-based risk stratification tools for oncologists, haemato-oncologists and cardiologists to use in their clinical practice to risk stratify oncology patients prior to receiving cancer therapies known to cause heart failure or other serious cardiovascular toxicities. Baseline risk stratification proformas are presented for oncology patients prior to receiving the following cancer therapies: anthracycline chemotherapy, HER2-targeted therapies such as trastuzumab, vascular endothelial growth factor inhibitors, second and third generation multi-targeted kinase inhibitors for chronic myeloid leukaemia targeting BCR-ABL, multiple myeloma therapies (proteasome inhibitors and immunomodulatory drugs), RAF and MEK inhibitors or androgen deprivation therapies. Applying these risk stratification proformas will allow clinicians to stratify cancer patients into low, medium, high and very high risk of cardiovascular complications prior to starting treatment, with the aim of improving personalised approaches to minimise the risk of cardiovascular toxicity from cancer therapies.
264 citations
Vilnius University1, Charles University in Prague2, Hospital Universitario La Paz3, National Institutes of Health4, National and Kapodistrian University of Athens5, Medical University of Vienna6, University of Paris7, University of Cyprus8, University of Göttingen9, American Heart Institute10, Uppsala University11, Lithuanian University of Health Sciences12, University of Bern13, University Medical Center Groningen14, Charité15, Clalit Health Services16, Tel Aviv University17, University of Bristol18, I.M. Sechenov First Moscow State Medical University19, University of Liège20, Leiden University21, Baker IDI Heart and Diabetes Institute22, Linköping University23, Utrecht University24, University of Parma25, Hannover Medical School26, Katholieke Universiteit Leuven27, Maastricht University28, Queen Mary University of London29, University Hospital of Basel30, University of Zurich31, Carlos III Health Institute32, Serbian Academy of Sciences and Arts33, University of Oslo34, Oslo University Hospital35
TL;DR: The role of echocardiographic parameters, including global longitudinal strain and three‐dimensional ejection fraction, are proposed and the protocol for baseline pre‐treatment evaluation and specific surveillance algorithms or pathways for anthracycline chemotherapy, HER2‐targeted therapies such as trastuzumab and vascular endothelial growth factor tyrosine kinase inhibitors are presented.
Abstract: Cardiovascular (CV) imaging is an important tool in baseline risk assessment and detection of CV disease in oncology patients receiving cardiotoxic cancer therapies. This position statement examines the role of echocardiography, cardiac magnetic resonance, nuclear cardiac imaging and computed tomography in the management of cancer patients. The Imaging and Cardio-Oncology Study Groups of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC) in collaboration with the European Association of Cardiovascular Imaging (EACVI) and the Cardio-Oncology Council of the ESC have evaluated the current evidence for the value of modern CV imaging in the cardio-oncology field. The most relevant echocardiographic parameters, including global longitudinal strain and three-dimensional ejection fraction, are proposed. The protocol for baseline pre-treatment evaluation and specific surveillance algorithms or pathways for anthracycline chemotherapy, HER2-targeted therapies such as trastuzumab, vascular endothelial growth factor tyrosine kinase inhibitors, BCr-Abl tyrosine kinase inhibitors, proteasome inhibitors and immune checkpoint inhibitors are presented. The indications for CV imaging after completion of oncology treatment are considered. The typical consequences of radiation therapy and the possibility of their identification in the long term are also summarized. Special populations are discussed including female survivors planning pregnancy, patients with carcinoid disease, patients with cardiac tumours and patients with right heart failure. Future directions and ongoing CV imaging research in cardio-oncology are discussed.
194 citations
Moscow State University1, Nizhny Novgorod State Medical Academy2, Russian Academy of Sciences3, Russian National Research Medical University4, I.M. Sechenov First Moscow State Medical University5, Peoples' Friendship University of Russia6, Saint Petersburg State University7, Rostov State Medical University8, Kazan State Medical University9, The Volgograd State Medical University10, Kuban State Medical University11
154 citations
Charles University in Prague1, University Hospital of Basel2, Vilnius University3, Washington University in St. Louis4, Duke University5, Georgetown University6, The Royal Marsden NHS Foundation Trust7, Vanderbilt University Medical Center8, University of Bern9, University of Pennsylvania10, European Institute of Oncology11, University of Paris12, National and Kapodistrian University of Athens13, University of Cyprus14, University of Vienna15, Charité16, University of Göttingen17, Tel Aviv University18, University of Zurich19, University of Warwick20, Serbian Academy of Sciences and Arts21, University of Ljubljana22, Academy for Urban School Leadership23, Leiden University24, American University of Beirut25, University Hospital of Bern26, Hospital Universitario La Paz27, University Medical Center Groningen28, Imperial College London29
TL;DR: Novel surveillance clinical pathways integrating cardiac biomarkers for cancer patients receiving anthracycline chemotherapy or trastuzumab biomarkers are presented and future direction in cardio‐oncology biomarker research is discussed.
Abstract: Serum biomarkers are an important tool in the baseline risk assessment and diagnosis of cardiovascular disease in cancer patients receiving cardiotoxic cancer treatments. Increases in cardiac biomarkers including cardiac troponin and natriuretic peptides can be used to guide initiation of cardioprotective treatments for cancer patients during treatment and to monitor the response to cardioprotective treatments, and they also offer prognostic value. This position statement examines the role of cardiac biomarkers in the management of cancer patients. The Cardio-Oncology Study Group of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC) in collaboration with the Cardio-Oncology Council of the ESC have evaluated the current evidence for the role of cardiovascular biomarkers in cancer patients before, during and after cardiotoxic cancer therapies. The characteristics of the main two biomarkers troponin and natriuretic peptides are discussed, the link to the mechanisms of cardiovascular toxicity, and the evidence for their clinical use in surveillance during and after anthracycline chemotherapy, trastuzumab and HER2-targeted therapies, vascular endothelial growth factor inhibitors, proteasome inhibitors, immune checkpoint inhibitors, cyclophosphamide and radiotherapy. Novel surveillance clinical pathways integrating cardiac biomarkers for cancer patients receiving anthracycline chemotherapy or trastuzumab biomarkers are presented and future direction in cardio-oncology biomarker research is discussed.
141 citations
Charité1, Medical University of Vienna2, University of Paris3, National and Kapodistrian University of Athens4, Hospital Universitario La Paz5, University of Ljubljana6, University of Zurich7, Monash University8, University of Bern9, University of Göttingen10, University Medical Center Groningen11, Imperial College London12, University of Naples Federico II13
TL;DR: This review paper summarizes the epidemiology and the prognostic implications of cancer occurrence in HF, the impact of pre‐existing HF on cancer treatment decisions and theimpact of cancer on HF therapeutic options, while providing some practical suggestions regarding patient care and highlighting gaps in knowledge.
Abstract: Cancer and heart failure (HF) are common medical conditions with a steadily rising prevalence in industrialized countries, particularly in the elderly, and they both potentially carry a poor prognosis. A new diagnosis of malignancy in subjects with pre-existing HF is not infrequent, and challenges HF specialists as well as oncologists with complex questions relating to both HF and cancer management. An increased incidence of cancer in patients with established HF has also been suggested. This review paper summarizes the epidemiology and the prognostic implications of cancer occurrence in HF, the impact of pre-existing HF on cancer treatment decisions and the impact of cancer on HF therapeutic options, while providing some practical suggestions regarding patient care and highlighting gaps in knowledge.
119 citations
Cited by
More filters
01 Jan 2020
TL;DR: Prolonged viral shedding provides the rationale for a strategy of isolation of infected patients and optimal antiviral interventions in the future.
Abstract: Summary Background Since December, 2019, Wuhan, China, has experienced an outbreak of coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Epidemiological and clinical characteristics of patients with COVID-19 have been reported but risk factors for mortality and a detailed clinical course of illness, including viral shedding, have not been well described. Methods In this retrospective, multicentre cohort study, we included all adult inpatients (≥18 years old) with laboratory-confirmed COVID-19 from Jinyintan Hospital and Wuhan Pulmonary Hospital (Wuhan, China) who had been discharged or had died by Jan 31, 2020. Demographic, clinical, treatment, and laboratory data, including serial samples for viral RNA detection, were extracted from electronic medical records and compared between survivors and non-survivors. We used univariable and multivariable logistic regression methods to explore the risk factors associated with in-hospital death. Findings 191 patients (135 from Jinyintan Hospital and 56 from Wuhan Pulmonary Hospital) were included in this study, of whom 137 were discharged and 54 died in hospital. 91 (48%) patients had a comorbidity, with hypertension being the most common (58 [30%] patients), followed by diabetes (36 [19%] patients) and coronary heart disease (15 [8%] patients). Multivariable regression showed increasing odds of in-hospital death associated with older age (odds ratio 1·10, 95% CI 1·03–1·17, per year increase; p=0·0043), higher Sequential Organ Failure Assessment (SOFA) score (5·65, 2·61–12·23; p Interpretation The potential risk factors of older age, high SOFA score, and d-dimer greater than 1 μg/mL could help clinicians to identify patients with poor prognosis at an early stage. Prolonged viral shedding provides the rationale for a strategy of isolation of infected patients and optimal antiviral interventions in the future. Funding Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences; National Science Grant for Distinguished Young Scholars; National Key Research and Development Program of China; The Beijing Science and Technology Project; and Major Projects of National Science and Technology on New Drug Creation and Development.
4,408 citations
3,645 citations
1,650 citations
Journal Article•
580 citations
TL;DR: De Boer et al. as mentioned in this paper reviewed the work of as mentioned in this paper and found that the authors of the paper were concerned with the authorship of the document and not the content of the documents.
Abstract: Document Reviewers: Rudolf A. de Boer (CPG Review Coordinator) (Netherlands), P. Christian Schulze (CPG Review Coordinator) (Germany), Magdy Abdelhamid (Egypt), Victor Aboyans (France), Stamatis Adamopoulos (Greece), Stefan D. Anker (Germany), Elena Arbelo (Spain), Riccardo Asteggiano (Italy), Johann Bauersachs (Germany), Antoni Bayes‐Genis (Spain), Michael A. Borger (Germany), Werner Budts (Belgium), Maja Cikes (Croatia), Kevin Damman (Netherlands), Victoria Delgado (Netherlands), Paul Dendale (Belgium), Polychronis Dilaveris (Greece), Heinz Drexel (Austria), Justin Ezekowitz (Canada), Volkmar Falk (Germany), Laurent Fauchier (France), Gerasimos Filippatos (Greece), Alan Fraser (United Kingdom), Norbert Frey (Germany), Chris P. Gale (United Kingdom), Finn Gustafsson (Denmark), Julie Harris (United Kingdom), Bernard Iung (France), Stefan Janssens (Belgium), Mariell Jessup (United States of America), Aleksandra Konradi (Russia), Dipak Kotecha (United Kingdom), Ekaterini Lambrinou (Cyprus), Patrizio Lancellotti (Belgium), Ulf Landmesser (Germany), Christophe Leclercq (France), Basil S. Lewis (Israel), Francisco Leyva (United Kingdom), AleVs Linhart (Czech Republic), Maja‐Lisa Løchen (Norway), Lars H. Lund (Sweden), Donna Mancini (United States of America), Josep Masip (Spain), Davor Milicic (Croatia), Christian Mueller (Switzerland), Holger Nef (Germany), Jens‐Cosedis Nielsen (Denmark), Lis Neubeck (United Kingdom), Michel Noutsias (Germany), Steffen E. Petersen (United Kingdom), Anna Sonia Petronio (Italy), Piotr Ponikowski (Poland), Eva Prescott (Denmark), Amina Rakisheva (Kazakhstan), Dimitrios J. Richter (Greece), Evgeny Schlyakhto (Russia), Petar Seferovic (Serbia), Michele Senni (Italy), Marta Sitges (Spain), Miguel Sousa‐Uva (Portugal), Carlo G. Tocchetti (Italy), Rhian M. Touyz (United Kingdom), Carsten Tschoepe (Germany), Johannes Waltenberger (Germany/Switzerland)
495 citations